Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Athira Pharma Inc
Healthcare
P/NCAV
0.62x
Ticker
ATHA
Exchange
NASDAQ
Country
United States
Close
2.04 $
Mkt Cap
77.6M $
EV
-13.0M $
NCAV Burn Rate
32.4%
Current Ratio
5.37
Debt/Equity
0.0
EV/REV
N/Ax
EV/EBIT
0.1x
EV/FCF
0.1x
Dilution
4.3% p.A
Total Net Income
-298.4M $
Cheapness
1.0%
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline consists of both blood brain barrier permeable and peripherally restricted drug candidates for the central nervous system (CNS), peripheral nervous system, and other indications. Its lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, small molecule positive modulator of the hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) system for CNS disorders. It is also evaluating other drug candidates for the potential treatment of neuropathic pain, amyotrophic lateral sclerosis, Parkinson-s disease, and other neurodegenerative diseases. Its ATH-1020 has completed a Phase I single ascending dose evaluation in healthy volunteers. Its ATH-1105 is a small molecule compound designed to be an orally available, once-daily treatment to enhance the HGF/MET system.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average